Trinity Biotech Secures Final Approval for Offshored Uni-Gold HIV Production Model
Trinity Biotech received local regulatory clearance to begin upstream manufacturing of its WHO-prequalified Uni-Gold HIV rapid test under a newly offshored and outsourced production model. The approval unlocks expected gross margin expansion, improved working capital efficiency and scalable capacity growth as part of the company’s Comprehensive Transformation Plan.
1. Final Regulatory Approval
Trinity Biotech has received full in-country regulatory clearance to commence upstream manufacturing of its WHO-prequalified Uni-Gold HIV rapid test under a new offshored and outsourced production model, marking the last major approval required for the initiative.
2. Offshore and Outsourced Production Model
The new manufacturing approach transitions upstream processes to a cost-efficient offshore platform, targeting gross margin expansion, improved working capital efficiency and scalable capacity to meet future global demand for Uni-Gold HIV tests.
3. Role in Transformation Plan
This approval represents a key component of the company’s Comprehensive Transformation Plan, designed to strengthen long-term financial metrics by reducing production costs and enhancing operational flexibility.
4. Implementation and Market Impact
With regulatory clearance secured, Trinity Biotech can now fully deploy its offshore manufacturing strategy, potentially accelerating supply chain efficiency and supporting growth in the global HIV rapid testing market.